Clinical and prognostic significance of expression of phosphoglycerate mutase family member 5 and Parkin in advanced colorectal cancer

Table 1 Baseline characteristics of patients with advanced colorectal cancer and the correlation with immunohistochemical expression of phosphoglycerate mutase family member 5 or Parkin, n (%)

Clinicopathologic characteristic	Cases	PGAM5		P value	Parkin		P value
		Low (n = 4)	High (n = 96)		Low (n = 29)	High (n = 71)
Age (yr)				0.332			0.927
< 61 (median)	49	1	48		14	35
≥ 61	51	3	48		15	36
Gender				0.440			0.586
Male	56	3	53		15	41
Female	44	1	43		14	30
Tumor site				0.230			0.468
Colon	26	0	26		9	17
Rectum	74	4	70		20	54
Size of the tumor, cm				0.776			0.816
≤ 4	43	2	41		13	30
> 4	57	2	55		16	51
Histological type				0.713			0.207
Mucinous	18	1	17		3	15
Non-mucinous	82	3	79		26	56
Degree of differentiation				0.649			0.559
Well/moderate	61	2	59		19	42
Poor/mucinous	39	2	37		10	29
Angiolymphatic and/or perineural invasion				0.681			0.350
Absent	96	4	92		27	69
Present	4	0	4		2	2
Tumor stage (TNM)				1.000			0.275
I-II	50	2	48		12	38
III-IV	50	2	48		17	33
Tumor invasion depth				0.871			0.143
T2-T3	54	2	52		19	35
T4	46	2	44		10	36
Lymph node status				0.936			0.364
N0	52	2	50		13	39
N1-N2	48	2	46		16	32
Distant metastasis				0.435			0.425
Absent	13	0	13		5	8
Present	87	4	83		24	63
CEA				0.744			0.718
Normal	58	2	56		16	42
High	42	2	40		13	29
CA19-9				0.105			0.301
Normal	39	0	39		9	30
High	61	4	57		20	41
P53				0.097			0.859
Normal	40	0	40		12	28
High	60	4	56		17	43
CDX2				0.344			0.489
Normal	18	0	18		4	14
High	82	4	78		25	57

PGAM5: Phosphoglycerate mutase family member 5; TNM: Tumor-node-metastasis; CEA: Carcinoembryonic antigen.